Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

an "enriched" enrollment, double-blind, placebo-controlled, randomized withdrawal study measuring the efficacy and safety of BEMA Buprenorphine in patients with moderate to severe chronic pain.  Patients meeting the designated study criteria undergo titration with BEMA Buprenorphine to a dose that is both effective and well-tolerated.  Those patients who identify an effective and well tolerated dose are then randomized to either continue their BEMA Buprenorphine dose or begin use of a placebo (BEMA film with no active drug) for twelve weeks.  The primary efficacy measure is the mean change in pain intensity from the time patients are randomized (to BEMA Buprenorphine or placebo) through to the end of the twelve week study period.  The study design described has been utilized for a number of the opioid analgesics approved by the FDA in recent years.  The study design includes an interim analysis to confirm the number of patients needed for adequate statistical power.  This interim analysis is part of the study design agreed upon with FDA and is included solely to provide assurance that the sample size is adequate to detect the effect difference between the active and placebo treatments. 

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada,
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... 28, 2015 A new report ... Industry Analysis, Trends, Opportunities, Growth and Forecast, 2014-2020", forecasts ... by 2020. The secondary syphilis testing would continue to ... Latin America , Middle East ... accounted for about 43% revenue share of the global ...
(Date:5/28/2015)... -- The recent flurry of PBM mergers and acquisitions ... to identify a pharmacy benefit manager that isn,t ... pharmacy chain, or other potentially conflicting entity. ... Rite Aid,s $2 billion acquisition of EnvisionRx, and ... billion are just the latest examples of the ...
(Date:5/28/2015)... WASHINGTON , May 28, 2015 ... resolving the Commission,s antitrust suit charging Cephalon, Inc. ... sleep-disorder drug Provigil. The settlement ensures that Teva ... will make a total of $1.2 billion available ... insurers, who overpaid because of Cephalon,s illegal conduct.  ...
Breaking Medicine Technology:Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 2Global Syphilis Testing Market is Expected to Reach $3.6 Billion, by 2020 - Allied Market Research 3Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 2Citizens Rx Addresses Recent PBM Consolidation and Rising Pharmacy Costs 3FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 2FTC Settlement of Cephalon Pay for Delay Case Ensures $1.2 Billion in Ill-Gotten Gains Relinquished; Refunds Will Go To Purchasers Affected By Anticompetitive Tactics 3
... Oct. 28 Rules-Based Medicine (RBM), a leading ... of CardiovascularMAP, a research tool designed specifically to ... cardiovascular disease (CVD.) Designed in collaboration with leading ... combines biomarkers most commonly associated with CVD progression ...
... , CORONA, Calif., Oct. 28 Watson Pharmaceuticals, ... pharmaceutical company, announced today that its subsidiary Watson ... Laboratories, Inc. on outstanding patent litigation related to ... , On August 19, 2008, Barr submitted an ...
Cached Medicine Technology:Rules-Based Medicine Introduces CardiovascularMAP(TM) Multiplex Biomarker Panel to Aid CVD Drug Development 2Rules-Based Medicine Introduces CardiovascularMAP(TM) Multiplex Biomarker Panel to Aid CVD Drug Development 3Watson and Barr Settle Lawsuit Over Oxytrol(R) 2
(Date:5/29/2015)... 2015 Belviq for weight loss ... prescription diet medication. In 2012, the FDA approved ... have a BMI >30. It is also approved ... one additional weight-related health condition such as high blood ... main function for weight loss focuses on the brain’s ...
(Date:5/28/2015)... May 28, 2015 External Counterpulsation (EECP/ECP) ... all over the United States. There are a growing ... who can experience symptoms of angina and these patients ... stents and/or bypass surgery. , “No option” patients are ... coronary artery disease that is considered unacceptable for heart ...
(Date:5/28/2015)... 28, 2015 AMVETS National Executive Director ... Commission on Care established by Congress to examine how ... , Appointed to the commission by Mitch McConnell, majority ... one of only 15 voting members on the panel, ... Accountability Act of 2014. The goal of the commission ...
(Date:5/28/2015)... Park Cities Pet Sitter is offering a 5-week ... starting Saturday, June 6th at 10:30am. The classes will ... in Dallas, with a maximum of six dogs allowed in ... with no class being held over the 4th of July ... this Intermediate-to-Advanced level class, dogs will solidify their practical behavior ...
(Date:5/28/2015)... New Jersey Plastic Surgeon and “NJ Top ... With over 30 years of experience in the ... Dr. Rafizadeh knows what it takes to achieve that ... involves the principles of proportion, harmony and balance. ... comfort and personalized care from the moment a patient ...
Breaking Medicine News(10 mins):Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 2Health News:Belviq for Weight Loss is Now Available to Qualified Diet Doc Patients Nationwide 3Health News:External Counterpulsation (EECP/ECP) a New Heart Disease Therapy Helps People of Calgary with Unstable Angina 2Health News:AMVETS Executive Director Stewart Hickey Appointed to Congressional Commission on Care 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 2Health News:Dallas-based Park Cities Pet Sitter to Offer “Training and Enrichment 2” Group Dog Training Class Beginning Saturday, June 6th, 2015. 3Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 2Health News:"NJ Top Doc", Dr. Farhad Rafizadeh is Excited to Offer New Services at his Plastic Surgery Practice 3
... analysis calls gap between these and lower-tier facilities ,disappointing, ... to the top-rated hospitals in the United States have ... patients admitted to other hospitals in the country, a ... independent health-care ratings organization, the analysis of 27 procedures ...
... February 29, 2008, PALO ALTO, Calif., Jan. ... announced today that the U.S. Food and,Drug Administration ... the,response by Solvay Pharmaceuticals, Inc. to the FDA ... Capsules. The,FDA has notified Solvay Pharmaceuticals that the ...
... PRINCETON, N.J., Jan. 31 Medarex, Inc.,(Nasdaq: MEDX ... at the,Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device,Conference ... The event will be,webcast live and will be available ... at http://www.medarex.com . An archived edition of the,presentation ...
... Ill., Jan. 31 Acura,Pharmaceuticals, Inc. (OTC Bulletin ... Stock Market(R) has approved the Company,s application to,list ... ("NASDAQ"). The,Company,s common stock will commence trading on ... "ACUR"., "We are pleased to join the ...
... In hopes of gaining a better,grasp on the ... on sales training tools and techniques to,provide their sales ... year of training and preparation is critical for success, ... approximately $10,500 in,the first year of employment, more than ...
... Prizes in Annual Essay Contest, TOMS RIVER, N.J., ... of the annual "WORD About Health",Contest during a special ... contest challenged students enrolled in Toms River intermediate schools,to ... their,understanding of nutrition and drug-free living. Over 1,900 students,submitted ...
Cached Medicine News:Health News:Top-Rated Hospitals Continue to Deliver Better Care 2Health News:Jazz Pharmaceuticals, Inc. Announces Submission of Complete Response to FDA Approvable Letter for LUVOX(R) CR 2Health News:Medarex to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference 2Health News:Acura Pharmaceuticals, Inc. Announces Approval to List Shares on NASDAQ and Effective Feb. 4, 2008 a New Trading Symbol: ACUR 2Health News:Vital Training Tools Elevate New Pharmaceutical Sales Reps into Top Performers During Critical First Year 2Health News:AMERIGROUP Foundation Announces Winners of 'Word About Health' Contest 2
... Solutions introduces its new multifunctional lithotripsy ... intuitive patient data management is the ... urological table. Lithoskop is an engineering ... covers all applications like lithotripsy, endourology, ...
... A surgically implanted bone growth stimulator ... EBI OsteoGen surgically implanted bone growth stimulator ... of nonunions when surgery is already planned ... concern. Because the OsteoGen is totally surgically ...
... of patients requiring cataract surgery following refractive ... created a challenge for surgeons, as calculating ... difficult. True corneal power following RK, ALK, ... measure by keratometry or topography. For example, ...
... just 248 grams. It boasts an ... of all rota table continuous flow ... outer diameter has been reduced to ... a large resection volume, while excellent ...
Medicine Products: